Table 2.
Objective response
| Bevacizumab and irinotecan | ||
|---|---|---|
| Response | Number of patients (N = 52) | % |
| Complete response | 0 | 0 |
| Partial response | 22 | 42.3 |
| Stable disease | 12 | 23.1 |
| Progressive disease | 18 | 34.6 |
| Disease control rate | 65.4 | |
| Overall response rate | 42.3 | |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.